Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis

Table 3

Characteristics of FOLFIRI treatment.

Time on FOLFIRI (months)
Median	8
Range	1–61
Protocol modification
Dose reduction (75%)	4/18%
Interval prolongation (qd21)	2/9%
Adverse events (no./%)
Peripheral neuropathy	21/95%
Peripheral neuropathy > grade 2	1/5%
Nausea and vomiting	16/73%
Nausea and vomiting > grade 2	0/0%
Diarrhea	5/23%
Diarrhea > grade 2	0/0%
Neutropenia	11/50%
Neutropenia > grade 2	3/14%
Thrombocytopenia	1/5%
Thrombocytopenia > grade 2	0/0%
Anemia	3/14%
Anemia > grade 2	0/0%
Treatment after disease progress (no./%)
Gemcitabine/NAB-paclitaxel	14/64%
Gemcitabine/erlotinib	1/5%
FOLFIRINOX re-escalation	3/14%
Best supportive care	4/18%